Vitamin E and retinopathy of prematurity. Follow-up at one year

Ophthalmology. 1985 Aug;92(8):1005-11. doi: 10.1016/s0161-6420(85)33913-1.

Abstract

Five hundred forty-five infants weighing less than 1501 g at birth were entered into a randomized, prospective study to determine the effect of high serum levels (5 mg/dL) of vitamin E used prophylactically to try to prevent or alter the natural course of retinopathy of prematurity (ROP) and its sequel, retrolental fibroplasia (RLF). Three hundred twenty-eight infants were available for the one- to two-year eye examination. Although there was a trend (P = 0.072) toward less severe RLF among vitamin E-treated infants, the incidence of RLF was 11/162 (6.8%) in the placebo treated (P) infants, and 12/166 (7.2%) in the vitamin E-treated (E) infants. The incidences of hyperopia, myopia, anisometropia, strabismus and amblyopia were also similar in both the P and E groups.

Publication types

  • Clinical Trial
  • Comparative Study
  • Randomized Controlled Trial
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Cicatrix / complications
  • Clinical Trials as Topic
  • Eye Diseases / epidemiology
  • Follow-Up Studies
  • Humans
  • Infant
  • Infant, Low Birth Weight
  • Infant, Premature, Diseases / drug therapy
  • Infant, Premature, Diseases / epidemiology
  • Infant, Premature, Diseases / prevention & control*
  • Prospective Studies
  • Random Allocation
  • Refractive Errors / classification
  • Retinal Diseases / complications
  • Retinal Diseases / drug therapy
  • Retinal Diseases / epidemiology
  • Retinal Diseases / prevention & control*
  • Retinopathy of Prematurity / prevention & control
  • Vitamin E / blood
  • Vitamin E / therapeutic use*

Substances

  • Vitamin E